Catheterization
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
1 program1
3.15% chlorhexidine as daily antiseptic on needleless access portPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Allergy Therapeutics3.15% chlorhexidine as daily antiseptic on needleless access port
SolventumChlorhexidine gluconate
Becton DickinsonPowerMe Midline Catheter
Clinical Trials (3)
Total enrollment: 474 patients across 3 trials
Study of Chlorhexidine as the Hub Antiseptic to Prevent Catheter Related Infections in Newborn Infants
Start: Jul 2007Est. completion: Aug 2008150 patients
Phase 4Unknown
Clinical Performance of a Chlorhexidine Antimicrobial Dressing
Start: Oct 2007Est. completion: Jan 200868 patients
Phase 2/3Completed
A Clinical Trial Evaluating the Effectiveness and Safety of the PowerMe Midline Catheter in the Chinese Population
Start: Jan 2021Est. completion: Jan 2022256 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.